Tonix Pharmaceuticals Holding (TNXP) Starts Presentation at LD Micro Main Event
Tonix Pharmaceuticals Holding (NASDAQ: TNXP) is a clinical-stage pharmaceutical company that develops medicines for common disorders of the central nervous system. The company's lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet; a phase III clinical stage for the treatment of PTSD; and phase II clinical stage for the treatment of military-related PTSD. For more information, visit the company's website at www.tonixpharma.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced…